(Reuters Health)—Many patients leaving the hospital don’t understand follow-up care plans because the instructions are tailored to people with higher reading levels and more education, a recent U.S. study suggests. The American Medical Association already recommends that written health information be targeted to a sixth grade audience because nearly half of the U.S. population is…
Articles by Natasha Yetman
Living with RA: Study Examines the Value of Patient Involvement in Creating Clinical Practice Guidelines
“The lived experience with RA is itself a valuable form of expertise,” writes Dr. Liana Fraenkel, MD, MPH, and her colleagues in their latest research. To examine the value of this expertise and how it can be incorporated into clinical practice guidelines, researchers developed 18 questions for which two panels—one physician dominated and one comprising entirely patients—would develop recommendations. For a majority of these questions, the patient panel made the same recommendations as the physician panel, with similar recommendation strengths…
Researchers Describe Controversial Study of Surgeon Training
(Reuters Health)—Whether surgical trainees should be able to work long shifts is a matter of fierce debate, and the methods of a controversial study aimed at answering that question were outlined in a top surgical journal. The results won’t be available until February. In the meantime, critics of the study say it exposed residents and…
The Microbiome’s Role in Inflammatory Arthritis
Despite the relative novelty of the human microbiome as an area of study, a substantial body of evidence has accumulated addressing its potential involvement in the pathogenesis of rheumatic disease. This review article explores the available data in animal and human studies, focusing on the role of the intestinal microbiome in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and the spondyloarthritidies (SpA)…
U.S. Signs Up 8.2 Million People for Insurance on HealthCare.gov
NEW YORK (Reuters)—The U.S. government signed up 8.2 million people for health insurance through the HealthCare.gov website through Dec. 19, including 2.1 million people from the insurers’ most sought-after demographic: those aged under 35, according to the top health official. That compares with the 6.4 million people who signed up or were automatically signed up…
New Blood Thinner ‘Antidote’ to Help Doctors Move Past Warfarin
NEW YORK (Reuters)—A new class of blood thinners that competes with widely used warfarin should get a boost next year when an “antidote” that can reverse the medications’ effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson & Johnson, and…
More Evidence Biomarkers Predict RA Relapse with DMARD Taper
NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…
People with Schizophrenia at Higher Risk of Osteoporosis
NEW YORK (Reuters Health)—Pooled data indicate that bone mineral density (BMD) is significantly lower in patients with schizophrenia than in healthy controls, according to Taiwanese researchers. Dr. Ping-Tao Tseng tells Reuters Health by email that the “evidence indicates the importance of further screening for the risk of osteoporosis in young-aged schizophrenic patients . . ….
Methotrexate for Ulcerative Colitis Yields Mixed Results
NEW YORK (Reuters Health)—Parenteral methotrexate was no better than placebo for achieving steroid-free remission of ulcerative colitis (UC) in the METEOR trial. But the drug should not be abandoned in all UC patients, researchers say. “Although METEOR failed to reach its primary endpoint, an important secondary endpoint was met. Our study suggests that methotrexate should…
NIH-Funded Trials Dip While Industry Trials Are on the Rise
(Reuters Health)—Every year since 2006 in the U.S., the number of clinical trials funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific…
- « Previous Page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- …
- 97
- Next Page »